Brokerages Set Halozyme Therapeutics, Inc. (NASDAQ:HALO) PT at $61.90

Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) have been assigned a consensus rating of “Hold” from the twelve research firms that are presently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and four have given a buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $61.90.

HALO has been the topic of several recent analyst reports. HC Wainwright restated a “buy” rating and issued a $72.00 price objective on shares of Halozyme Therapeutics in a report on Thursday, May 29th. Wells Fargo & Company increased their target price on shares of Halozyme Therapeutics from $60.00 to $65.00 and gave the stock an “equal weight” rating in a report on Wednesday, May 7th. Benchmark lowered shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, May 7th. Morgan Stanley lowered shares of Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and reduced their target price for the stock from $73.00 to $62.00 in a report on Wednesday, May 14th. Finally, Leerink Partners lowered shares of Halozyme Therapeutics from a “market perform” rating to an “underperform” rating and set a $47.00 target price on the stock. in a report on Tuesday, May 13th.

Halozyme Therapeutics Stock Performance

Shares of HALO stock opened at $53.92 on Thursday. The firm’s 50 day moving average price is $57.27 and its 200-day moving average price is $56.22. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80. Halozyme Therapeutics has a one year low of $42.01 and a one year high of $70.51. The firm has a market cap of $6.64 billion, a P/E ratio of 15.72, a P/E/G ratio of 0.42 and a beta of 1.19.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported $1.11 EPS for the quarter, topping the consensus estimate of $0.98 by $0.13. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The firm had revenue of $264.86 million for the quarter, compared to analyst estimates of $231.21 million. During the same period in the prior year, the business posted $0.79 EPS. The business’s revenue for the quarter was up 35.2% compared to the same quarter last year. As a group, equities research analysts predict that Halozyme Therapeutics will post 4.73 EPS for the current year.

Insider Activity

In related news, Director Jeffrey William Henderson sold 503 shares of the stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $64.05, for a total value of $32,217.15. Following the transaction, the director now directly owns 33,108 shares of the company’s stock, valued at $2,120,567.40. This trade represents a 1.50% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 2.40% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of HALO. Louisiana State Employees Retirement System grew its position in shares of Halozyme Therapeutics by 0.6% in the 4th quarter. Louisiana State Employees Retirement System now owns 35,300 shares of the biopharmaceutical company’s stock valued at $1,688,000 after buying an additional 200 shares during the last quarter. Davidson Capital Management Inc. grew its position in shares of Halozyme Therapeutics by 111.2% in the 4th quarter. Davidson Capital Management Inc. now owns 56,639 shares of the biopharmaceutical company’s stock valued at $2,708,000 after buying an additional 29,826 shares during the last quarter. Castellan Group grew its position in shares of Halozyme Therapeutics by 2.3% in the 4th quarter. Castellan Group now owns 116,470 shares of the biopharmaceutical company’s stock valued at $5,568,000 after buying an additional 2,672 shares during the last quarter. Vontobel Holding Ltd. purchased a new position in shares of Halozyme Therapeutics in the 4th quarter valued at $377,000. Finally, Rhumbline Advisers grew its position in shares of Halozyme Therapeutics by 1.4% in the 4th quarter. Rhumbline Advisers now owns 410,508 shares of the biopharmaceutical company’s stock valued at $19,626,000 after buying an additional 5,833 shares during the last quarter. 97.79% of the stock is owned by hedge funds and other institutional investors.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.